IL-10 down-regulates human microglial IL-8 by inhibition of NF-kappaB activation.
In the present study, we tested the hypothesis that interleukin (IL)-10 down-regulates human microglial cell IL-8 release by inhibiting activation of nuclear factor kappa B (NF-kappaB). Immunohistochemical staining demonstrated that IL-10 markedly suppressed lipopolysaccharide (LPS)- and IL-1beta-stimulated IL-8 expression. NF-kappaB involvement was suggested by the finding that pyrrolidinedithiocarbamate, a known inhibitor of NF-kappaB activation, blocked LPS- and IL-1beta-induced IL-8 production. Consistent with our hypothesis, IL-10 treatment of LPS- and IL-1beta-stimulated microglia was associated with a marked decrease in NF-kappaB translocation from the cytoplasm to the nucleus.
Ehrlich
L C
LC
Institute for Brain and Immune Disorders at the Minneapolis Medical Research Foundation, University of Minnesota Medical School, 55404, USA.
Hu
S
S
Peterson
P K
PK
Chao
C C
CC
D015536:Down-Regulation; D006801:Humans; D007150:Immunohistochemistry; D016753:Interleukin-10 / Q000494:pharmacology*; D016209:Interleukin-8 / Q000378:metabolism*; D008070:Lipopolysaccharides / Q000494:pharmacology; D017628:Microglia / Q000187:drug effects* / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism*
D016209:Interleukin-8; D008070:Lipopolysaccharides; D016328:NF-kappa B; D016753:Interleukin-10